|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic phosphopeptide derived from human Opioid Receptor sigma around the phosphorylation site of Ser363 (T-P-SP-D-G)|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.4, with 150mM NaCl, 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
OPRD1 is an Opioid Receptor that is involved in the control of anxiety, depression, and pain. It is a promising target in the therapy of mood-altering disorders and drug addiction. Delta and kappa opioid receptors function synergistically by forming heterodimers. OPRD1 expression has been reported primarily in the brain. High OPRD1 expression has been documented in the cortex, caudate, hippocampus, nucleus accumbens, and putamen; low OPRD1 expression has been identified in the cerebellum, hypothalamus, substantia nigra, and thalamus. OPRD1 expression is reduced in the putamen and amygdala of Alzheimers patients and in the putamen in Parkinsons disease.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.